















Recurrent spontaneous abortion (RSA) 
has been associated with many etiologies. It 
occurs in 1 to 2% of all women of reproductive 
age.1 An association between autoantibod-
ies and gestational loss has been identifi ed, 
especially for antiphospholipid antibodies 
(APA). Other antibodies such as those against 
thyroid components, nuclear antigens and 
deoxyribonucleic acid (DNA) fractions2 have 
also been associated with gestational loss and 
preeclampsia.3
Venous thrombosis in the mother has 
been associated with RSA in several series.4,5 
Acquired thrombophilia is associated with 
thrombophilic factors with no inherited char-
acteristics, such as anticardiolipin antibody 
(ACA) and lupus anticoagulant (LA). 
The detection of APA such as ACA and 
LA seems to be higher in the fi rst trimester in 
women who have antiphospholipid syndrome 
(APS), but positive transient results have been 
detected in women without APS. APS and 
implantation site thrombosis can justify 5 to 
10% of RSA and the mechanism of action is 
not completely clear.6 
LA is an immunoglobulin that in-
terferes with one or more phospholipid-
dependent coagulation tests and leads to 
thromboembolic predisposition.7 Patients 
with persistent elevated results are at risk 
of arterial and venous thrombosis, gesta-
tional loss and other complications, such 
as intrauterine growth restriction.5 Simul-
taneous presence of LA and other APA 
seems to have an important association 
with early abortion.8 Inherited factors for 
thrombophilia include protein C, protein S 
and antithrombin III (ATIII) deficiencies, 
factor V Leiden and G20210A mutations 
in the prothrombin gene and C677T mu-
tation in the methylenetetrahydrofolate 
reductase (MTHFR) gene.
Other APA have also been associated 
with RSA, such as antiphosphatidylserine 
and antiphosphatidylethanolamine. Some of 
these antibodies are directed to phosphatidyl 
ethanolamine-binding plasma proteins, such as 
high molecular weight kininogen.9 The kinino-
gen concentration in reproductive tissues and 
plasma has been reported to fl uctuate during 
ovulation, pregnancy and parturition.10 What 
governs the fl uctuation of kininogen concen-
trations remains to be elucidated. Sugi et al.9 
demonstrated a strong association between RSA 
and antiphosphatidylethanolamine antibodies. 
Studying women with recurrent in vitro fertil-
ization failure, Matsubayashi et al.11 found an 
increased incidence of IgG-antiphosphatidyl-
serine, when compared with RSA patients. 
Markers of defi ciency in folate metabolic 
pathways have been associated with RSA, in-
cluding elevated levels of plasmatic homocys-
teine.12,13 Several inherited and acquired con-
ditions can cause hyperhomocysteinemia,14 
leading to increased risk of stroke, myocardial 
infarction and peripheral arterial disease.15 The 
C677T mutation in the MTHFR gene leads 
to a reduction in the activity of this enzyme, 
resulting in increased levels of plasmatic ho-
mocysteine.16 Several series have suggested an 
association between hyperhomocysteinemia 
and RSA.12,13 Other gestational complications, 
such as preeclampsia, abruptio placentae, 
intrauterine growth restriction and stillbirth 
have been associated with homozygous 
C677T in the MTHFR gene.17 
Proteins C and S are natural plasmatic 
anticoagulants.15 The prevalence of protein 
C defi ciency in women with gestational loss 
ranges from 4.7%13 to 25.5%.18 A high preva-
lence of protein S defi ciency has been found 
in women with two or more spontaneous 
abortions: 44.8%. ATIII defi ciency has also 
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CONTEXT: Recurrent spontaneous abortion 
(RSA) has been associated with venous throm-
bosis in the mother. Acquired and inherited 
thrombophilia factors are possible causes. 
OBJECTIVE: To evaluate the association 
between thrombogenic factors and recurrent 
spontaneous abortion. 
TYPE OF STUDY: Case-control study.
SETTING: Centro de Atenção Integral à 
Saúde da Mulher, Universidade Estadual de 
Campinas. 
METHODS: 40 ml of blood was collected from 
88 women attending an RSA clinic and 88 fertile 
women attending a family planning clinic, to 
evaluate the presence of acquired and inherited 
thrombophilia factors. Anticardiolipin antibod-
ies (ACA), lupus anticoagulant and defi ciencies 
of proteins C and S and antithrombin III were 
evaluated by enzyme-linked immunosorbent assay 
(ELISA), dilute Russell Viper Venom time (dRVVT), 
coagulometric and chromogenic methods. DNA 
was amplifi ed by the polymerase chain reaction 
(PCR) to study factor V Leiden and G20210A muta-
tions in the prothrombin gene and C677T mutation 
in the methylenetetrahydrofolate reductase (MTHFR) 
gene. Data were analyzed using odds ratios and a 
regression model for age adjustment. Fisher’s exact 
test was used to evaluate statistical relationships 
between associated factors and RSA. 
RESULTS: ACA was detected in 11 women 
with RSA and one fertile woman. Heterozygous 
C677T was detected in 59 women with RSA and 
35 fertile women. Concomitant presence of ACA 
and C677T was found in eight women with RSA 
and no fertile women (p < 0.01). 
DISCUSSION: The meaning of the association 
between C677T mutation in the MTHFR gene and 
ACA is still not clear. It is possible that an inherited 
factor that alone would not strongly predispose a 
woman to thrombosis could, when associated with 
an acquired factor, start the process and increase 
the likelihood of thrombosis expression.
CONCLUSIONS: ACA and C677T in the 
MTHFR gene are statistically associated with 
RSA. The association of these two conditions is a 
new fi nding in thrombogenic factors and RSA. 
KEY WORDS: Methylenetetrahydrofolate 
reductase (NADPH2) Thrombophilia. Throm-
bosis. Antiphospholipid syndrome. Anticar-
diolipin antibodies.
16
A mutation in the factor V gene has been 
identified as the molecular basis for acti-
vated protein C (aPC) resistance and has been 
named factor V Leiden. This leads to a hyper-
coagulable state.20 Dizon-Townson et al.21 did 
not detect any no association between RSA 
and factor V Leiden when studying women 
with RSA and fertile women. Despite this, a 
clear association between RSA and factor V 
Leiden was detected by Foka et al.22 
The G to A transition at the 20210 posi-
tion in the prothrombin gene is associated 
with elevated prothrombin levels and is a risk 
factor for thrombosis.23 Studying 80 women 
with RSA and 100 fertile women, Foka et al.22 
detected a higher frequency of preeclampsia, 
abruptio placentae, intrauterine growth re-
striction and stillbirth among those who were 
carriers of this mutation.
It is well established that inherited or 
acquired thrombophilic factors and their com-
binations can lead to increased risk of throm-
bosis.6 These combinations have also been 
associated with 2.2 to 14.3 times greater risk of 
RSA.24 The objective of the present study was 
to evaluate the association between the presence 
of thrombophilic factors and RSA.
METHODS
This was a case-control study that included 
88 women with RSA who were sequentially at-
tending an RSA clinic at Universidade Estadual 
de Campinas (Centro de Atenção Integral à 
Saúde da Mulher) as outpatients (Group 1) 
and 88 fertile women with at least one suc-
cessful pregnancy who were attending a family 
planning clinic at the same institution (Group 
2), from January 1999 to August 2000. The 
women in Group 2 had no history of RSA, 
stillbirth, thromboembolic episodes, arte-
rial hypertension, bad obstetrics or low birth 
weight. The patients in Group 1 were matched 
with the controls in Group 2 by age (five-year 
groups) and race (white or non-white). 40 ml 
of blood was collected to evaluate the presence 
of acquired (ACA and LA) and inherited factors 
(protein C, protein S and ATIII deficiencies, 
factor V Leiden and G20210A mutations in 
the prothrombin gene and C677T mutations 
in the MTHFR gene). 
Enzyme-linked immunosorbent assay 
(ELISA) was performed as previously de-
scribed,25 using high positive controls with 
known immunoglobulin G (IgG) and immu-
noglobulin M (IgM) concentrations (calibra-
tion sera LAPL-MP-005 and LAPL-GP-005 
from Louisville, Kentucky) and a normal 
donor as the negative control, in order to 
detect ACA. For quantitative determination 
of ACA, ELISA was used according to the 
manufacturer’s instructions and the standard 
ELISA procedures. In-house calibrators were 
used for standardization. Negative controls 
were included in the assays to confirm 
negative test results. These negative controls 
consisted of negative serum tested in our 
laboratory according to standard procedures. 
Positive test results for patients were selected 
by means of positive controls from Louisville. 
The absorbance was determined using a 
photometer set at 450 nm. The cutoff values 
predefined by the manufacturers were: IgG 
> 20 units and IgM > 20 units. The inter-
assay variation was 2.9-7.4% for IgG and 
2.3-5.1% for IgM. Mean values were also 
determined, and the results were compared 
using multiples of the mean. 
LA was detected by the dilute Russell 
Viper Venom Time (dRVVT), using the Or-
ganon Teknika kit: ViperquikTM LA-test and 
ViperquikTM LA-check. The final result was 
expressed as a relationship between “test” and 
“check” results. When this ratio was greater 
than 1.20, a confirmatory test was performed 
using a 50% mixture. Results greater than 2.0 
were considered positive.
Protein S (PS) activity was evaluated via 
the coagulometric method using the Bioclot 
PS kit. Normal diluted plasma was mixed with 
PS-deficient plasma. This mixture was activat-
ed by activated factor X + activated protein C 
+ phospholipids. After the addition of calcium 
chloride, the prolongation of clotting time was 
considered to be proportional to the protein S 
concentration in the patient’s plasma. Normal 
activity ranged from 55% to 160%.
Protein C activity was evaluated by the 
prolongation of the activated partial thrombo-
plastin time (APTT), using southern copper-
head snake poison to activate it. The protein 
C assay was performed using the Dade kit 
from Baxter Diagnostics, Inc. Normal activity 
ranged from 72% to 142%.
ATIII functional levels were determined 
using plasma diluted with ATIII, heparin and 
excess thrombin. An ATIII-thrombin-heparin 
complex was formed, and the remaining 
thrombin catalyzed p-nitroaniline releases on 
a chromogenic substrate. These were mea-
sured at 405 nm and viewed on a calibration 
curve. The Chromostrate® kit from Organon 
Teknika was used, and normal values ranged 
from 85% to 125%.
Genomic DNA was extracted from periph-
eral blood by a standard method.26 The poly-
merase chain reaction (PCR) was used to assay 
the factor V Leiden mutation, the thermolabile 
MTHFR C677T mutation and the prothrom-
bin G20210A mutation. Amplification of fac-
tor V Leiden was performed using a mixture 
of 54 mM Tris HCl (pH 8.8), 5.4 mM MgCl
2
, 







DMSO, 8 mM β-mercaptoethanol, 0.4 mg/ml 
BSA, 0.8 mM of each nucleoside triphosphate, 
200 ng of each forward and reverse primer, 
250 to 500 ng of genome DNA and 2U Taq 
polymerase. The amplification was performed 
for 36 cycles of 91° C (40 seconds), 55° C (40 
seconds) and 71° C (two minutes). 
Table 1. Thrombophilic factor distribution in 88 women with recurrent abortion (Group 1) and 88 fertile women (Group 2)  
attended at an outpatient clinic in Brazil
Group 1 
     n               (%)
Group 2 
   n          (%)
OR
(95% CI)
Age-adjusted OR (1) 
(95% CI)
Anticardiolipin antibodies 11 (12.5) 1 (1.1) 12.4 (1.5 to 98.5) 12.9 (1.5 to 109.5)
Lupus anticoagulant 1 (1.1) 0 (0) - -
Protein S deficiency 1 (1.1) 0 (0) - -
Protein C deficiency 2 (2.3) 0 (0) - -
AT III deficiency 1 (1.1) 0 (0) - -
Factor V Leiden 3 (3.4) 0 (0) 7.2 (0.3 to 142.4) -
G20210A prothrombin 1 (1.1) 1 (1.1) 1.0 (0.06 to 16.2) 1.0 (0.04 to 22.8)
C677T mutation in MTHFR gene 59 (67.0) 35 (39.8) 3.1 (1.7 to 5.7) 3.3 (1.6 to 6.6)
(1) Age adjustment was performed using a multiple regression model.
OR = odds ratio; CI = confidence interval; MTHFR = methylenetetrahydrofolate reductase.
Sao Paulo Med J. 2005;123(1):15-20.
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For MTHFR and prothrombin, ampli-
fications were performed in separate 50 µl 
reactions containing 10 mM Tris HCl (pH 
8.3), 50 mM KCl, 1.5 mM MgCl
2
, 0.2 mM 
of each nucleoside triphosphate, 0.4 µM of 
each forward and reverse primer and 2.5U of 
Taq polymerase. The PCR parameters were 
38 cycles of 94° C (30 seconds), 54° C (30 
seconds) and 72° C (30 seconds). The initial 
cycle was preceded by 9 minutes at 94° C, so 
as to activate AmpliTaq Gold polymerase in 
addition to denaturing the template, and the 
last cycle was followed by 5 minutes at 72° C. 
The PCR products were digested with the ap-
propriate restriction enzyme. After digestion, 
PCR products were submitted to electropho-
resis on 2% agar minigels containing ethidium 
bromide at 120 V for 1 hour.
For factor V Leiden, MnII digestion of 
the 267-bp PCR product yielded fragments 
of 163, 67 and 37 bp for the normal allele. 
The digestion products of the mutant allele 
were 200 and 67 bp. For MTHFR, HynfI 
did not cleave the 198-bp PCR product of 
the normal allele, whereas the mutant allele 
yielded fragments of 175 bp and 23 bp after 
HinfI digestion. 
For prothrombin, HindIII digestion 
yielded intact 345-bp product for the normal 
allele and two fragments of 322 and 23 bp for 
the mutant allele. For each locus, heterozygous 
individuals exhibited both normal and mutant 
digestion products. The PCR assay controls 
included DNA from a subject with subject, 
a normal subject and a blank water run for 
each analysis.
The data were analyzed using the odds 
ratio (OR) and a regression model for age-
adjustment. Fisher’s exact test was used to 
evaluate statistical relationships between 
RSA and the associated factors. The results 
were considered statistically significant when 
p values were less than 5%, for alpha = 0.05 
and beta = 0.20.
The ethical principles of the Helsinki 
Declaration of the World Medical Association 
were followed in this study. The Ethics Com-
mittee of Universidade Estadual de Campinas, 
Brazil, approved this study.  
RESULTS
The mean age was 30.4 years for Group 
1 and 29.7 for Group 2. The total number 
of pregnancies for patients from Group 1 
was 346, which ended as 26 deliveries and 
320 spontaneous abortions. In Group 2, the 
total number of pregnancies was 181, and all 
of them ended as deliveries. In each group 
studied, 61.4% of the women were white. In 
Table 2. Homozygous and heterozygous C677T mutation in the methylenetetrahy-
drofolate reductase gene in 88 women with recurrent abortion (Group 1) and 88 
fertile women (Group 2) attended at an outpatient clinic in Brazil
C677T mutation in MTHFR gene
Group 1 Group 2
p
(n) % (n) %
Homozygous, TT [a] 12 13.6 9 10.2 a versus c = 0.06
Heterozygous, CT [b] 47 53.4 26 29.5 b versus c = 0.0003
Normal, CC [c] 29 33.0 53 60.2
Total 88 100.0 88 100.00
MTHFR = methylenetetrahydrofolate reductase.
Table 3. Methylenetetrahydrofolate reductase gene allele distribution in 88 women 
with recurrent abortion (Group 1) and 88 fertile women (Group 2) attended at an 
outpatient clinic in Brazil
Allele
Group 1 Group 2
p
(n) % (n) %
Mutant (T) 71 40.3 44 25.0 0.002
Normal (CC) 105 59.7 132 75.0
Total 176 100.0 176 100.00
Group 1, 55.7% had had three pregnancies 
and 44.3% had had four or more. In Group 2, 
36.4% had had just one pregnancy. In Group 
1, 64.8% had had three gestational losses and 
35.2% had had four or more losses. ACA was 
detected in eleven women from Group 1 and 
in one woman from Group 2 (OR 12.4; 1.5 to 
98.5). The C677T mutation in the MTHFR 
gene was detected in 59 women from Group 
1 and 35 from Group 2 (OR 3.1; 1.7 to 5.7). 
These results can be observed in Table 1.
Table 2 shows the distribution of homo-
zygous and heterozygous C677T mutation 
in the two groups. A statistically significant 
difference was found when women with 
heterozygous mutation were compared with 
normal women.
Table 3 shows the allele distribution of 
C677T mutation between the groups studied. 
The mutant allele (T) was found in 40.3% 
of the women in Group 1 and in 25% of the 
women in Group 2.
No statistically significant differences were 
detected in the distribution of thrombophilic 
factors when patients were divided into white 
and non-white skin color.
The analysis of associated factors and their 
comparison between the groups studied showed 
that ACA and the heterozygous C677T muta-
tion in the MTHFR gene were simultaneously 
present in eight women from Group 1 and no 
one from Group 2, and this difference was 
statistically significant. The association between 
ACA and the homozygous C677T mutation 
in the MTHFR gene showed no statistical 
difference between the two groups; nor did 
the associations between ACA and the other 
thrombophilic factors studied. These relation-
ships can be seen in Table 4.
Likewise, the associations between the 
heterozygous C677T mutation in the MTHFR 
gene and the other factors studied showed no 
statistically significant difference between the 
two groups. The homozygous C677T mutation 
in the MTHFR gene showed no association 
with any thrombophilic factor studied.
DISCUSSION
In this study we looked for associations of 
inherited and acquired thrombophilic factors 
among patients with and without recurrent 
spontaneous abortions. Patients were matched 
by age, in order to try to minimize any possible 
unknown effect of age variation on RSA, or 
any possible effect of acquired factors (ACA 
and LA) on older women, regardless of the 
fact that no differences in the frequencies 
of these antibodies have been described for 
several age groups.27
It is known that the prevalence of genetic 
diseases varies in different races. As the Bra-
zilian population is highly heterogeneous, 
patients were also matched by race. A higher 
prevalence of factor V Leiden among Cauca-
sians has been described.28 It is possible that 
other mutations also present higher prevalence 
in this racial group. In the Brazilian popula-
tion, a higher prevalence of factor V Leiden has 
been detected in Caucasians, and it has rarely 
been detected in black people and Indians.29
The mean number of pregnancies was 
higher in Group 1. This result was expected, 
since the definition of RSA includes women 
with at least three spontaneous abortions. 
Sao Paulo Med J. 2005;123(1):15-20.
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36.4% of the women in Group 2 were pri-
miparous. Although we could not know how 
the next pregnancies would develop for this 
group, primiparous women were included as 
participants in the control group, in the same 
way as previously described in other series.30,31 
After one successful pregnancy, approximately 
3% of women will experience a spontaneous 
abortion.1 Considering this probability, only 
one woman from Group 2 would be expected 
to have this complication and this proportion 
would not be enough to change our results.  
ACA positivity occurred in 12.5% of the 
women who had RSA, and this coincides with 
the results in the literature.5 Among fertile 
women, it was detected in 1.1%. The preva-
lence of ACA described in normal obstetric 
populations ranges from 2.9 to 3.6%.32 
LA was detected in one patient from 
Group 1 and none from Group 2. Several 
series have been described that show an as-
sociation between LA and RSA.5,8 However, 
LA levels can vary during pregnancy,7 and 
persistently elevated levels are strongly associ-
ated with gestational loss.5 We did not find a 
good correlation between this test and RSA 
in this group of patients. There is a chance 
that this factor is not an important one for 
our population.
The prevalence of deficiencies of protein 
C, protein S and ATIII did not differ between 
the groups studied. A higher risk of spontane-
ous abortion in women with these deficiencies 
has been reported.33 Since protein C deficiency 
can affect 10 to 15% of young individuals with 
recurrent venous thrombosis20 and protein S 
deficiency occurs in 2.2% of patients with 
venous thrombosis,15 we investigated whether 
thrombosis at an implantation site could lead 
to recurrent abortion in women with these de-
ficiencies. This hypothesis was not confirmed 
by our results. Two women from Group 1 and 
none from Group 2 had protein C deficiency. 
As the incidence of this deficiency in the 
general population is 1/33,000 individuals,15 
a statistically significant difference might 
perhaps be detected with a greater number 
of patients. 
Women of reproductive age who are 
deficient in protein C, protein S or ATIII 
have a three times higher risk of thromboem-
bolic disease than do men of the same age.34 
Women with serious effects from a stroke or 
myocardial infarction may have more dif-
Table 4. Associations between anticardiolipin antibodies and other thrombophilic 
factors: distribution in 88 women with recurrent abortion (Group 1) and 88 fertile 
women (Group 2) attended at an outpatient clinic in Brazil
Factor associations
Group 1 Group 2
p*
(n) % (n) %
ACA with: Lupus anticoagulant 0 0 0 0 1.00
Protein C deficiency 1 1.1 0 0 1.00
Protein S deficiency 0 0 0 0 1.00
ATIII deficiency 1 1.1 0 0 1.00
Leiden factor V 0 0 0 0 1.00
G20210A prothrombin 0 0 0 0 1.00
Heterozygous C677T 8 9.1 0 0 < 0.01
Homozygous C677T 0 0 0 0 1.00
Total (10) (11.3) (0) (0)
* Fisher’s exact test. ACA = anticardiolipin antibody.
Table 5. List of some series with or without an association between factor V Leiden 
and recurrent spontaneous abortion
Author Year Cases Controls p
Rai et al.30 1996 70 70 0.02
Balash et al.31 1997 55 50 NS
Dizon-Townson et al.21 1997 40 25 NS
Grandone et al.37 1997 43 118 0.011
Pauer et al.38 1998 84 84 NS
Kutteh et al.39 1999 50 50 NS
Souza et al.40 1999 56 384 0.03
Foka et al.22 2000 80 100 0.003
Wramsby et al.41 2000 84 69 0.024
NS = not significant.
ficulty becoming mothers, as much due to 
their clinical condition as due to restrictions 
on social relations. Thus, the evaluation of 
women with RSA could exclude serious cases 
in an involuntary manner, thereby modifying 
the results.
There were no statistically significant dif-
ferences in the frequencies of factor V Leiden 
and G20210A mutation in the prothrombin 
gene between the two groups. The literature 
shows large variation in the importance of 
these mutations in relation to RSA. Some se-
ries have demonstrated an association between 
activated protein C resistance and abortions,30 
but the picture is not so clear when trying to 
implicate factor V Leiden as responsible for 
this resistance in the abortion series.35
Some authors have confirmed an asso-
ciation between factor V Leiden and RSA, 
but others have not, as can be seen in Table 
5. Our results did not demonstrate such an 
association. Although three women from 
Group 1 were detected as factor V Leiden 
carriers, there were none in Group 2. Again, 
the use of a larger sample size would perhaps 
give rise to a significant difference between 
the two groups. 
G20210A carriers have higher prothrom-
bin levels and are at greater risk of thrombosis 
than are controls.23 A higher risk of primary 
abortion was detected in women with this 
mutation than in controls.22 Our results, with 
a similar number of patients, did not show a 
significant difference in G20210A prevalence 
between the groups studied. More studies are 
necessary for a definitive conclusion about 
the importance of this mutation for RSA to 
be reached.
The evaluation of the C677T mutation in 
the MTHFR gene resulted in curious data. We 
observed an association of this mutation with 
RSA, but such an association is not completely 
clear in the literature. Some authors agree that 
C677T, as a cause of hyperhomocysteinemia, 
could lead to RSA,17,22 but others do not.36,37
Homozygous C677T was detected in 
twelve women from Group 1 and in nine from 
Group 2. This difference was not significant. 
The high number of women with homozy-
gous C677T MTHFR who had successful 
pregnancies (nine women from Group 2) 
suggests that this mutation is not an essential 
condition for a bad gestational result. None 
of these nine women had ACA in association 
with homozygous C677T MTHFR.
Heterozygous C677T was found in 
47 women from Group 1 and in 26 from 
Group 2, and this difference was statisti-
cally significant. These data do not agree 
Sao Paulo Med J. 2005;123(1):15-20.
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with the literature. Some series in which 
C677T is classified as homozygous or 
heterozygous have shown a clear predomi-
nance of statistically significant homozy-
gosity in RSA.16,21 Lissak et al.38 described 
the importance of heterozygous C677T 
in RSA, but stated that more series would 
be necessary to confirm this. Homozygous 
individuals have high homocysteine levels, 
but increased levels can also be seen in 
heterozygous individuals. 
Nonetheless, the allele frequency of the 
C677T mutation in the MTHFR gene was 
higher in Group 1, with a statistically signifi-
cant difference between the two groups. This 
may direct new investigations towards the 
importance of heterozygous C677T mutation 
in women with RSA.
The concept that several factors interact 
to create thrombosis is well established.39 
The action of thrombophilic factors dur-
ing placentation may become amplified, 
thereby giving rise to modifications in pla-
cental circulation. These events could lead 
to spontaneous abortion or other gestational 
complications, such as intrauterine growth 
restriction and stillbirth. 
Several congenital and acquired factors 
must act together to suppress the potent an-
tithrombotic mechanism.39 The association of 
ACA and heterozygous C677T mutation was 
detected in eight women from Group 1 and 
none from Group 2, and this difference was 
statistically significant. 
The meaning of this association is still not 
clear. It is possible that an inherited factor that 
alone would not strongly predispose a woman 
to thrombosis could, when associated with an 
acquired factor, start the thrombosis process.
The association between heterozygous 
C677T mutation in the MTHFR gene and 
ACA may increase the likelihood of throm-
bosis expression. It is known that persistently 
elevated serum levels of ACA are associated 
with RSA.40 Positive results for ACA may 
be the starting point for the process of 
thrombosis. We believe that this kind of as-
sociation may be the key to understanding 
the mechanisms for several diseases, such as 
RSA, cancer or cardiac infarction, and should 
be further investigated.
There is no evidence in the literature that 
this kind of association is absolutely necessary 
for the full manifestation of the antiphospho-
lipid syndrome. However, it is possible that an 
inherited factor, such as C677T, may act as a ge-
netic predisposing factor that interacts with the 
antiphospholipid antibodies to fully manifest 
their clinical aspects. Moreover, we cannot state 
whether such associations are the cause of the 
antiphospholipid syndrome or whether C677T 
is the inducer of anticardiolipin antibodies. But 
we can wonder whether this association might 
be necessary for ACA manifestation.
CONCLUSIONS
ACA and heterozygous C677T mutation 
in the MTHFR gene presented a statistical as-
sociation with RSA. The association of these 
two conditions is a new finding in thrombo-
genic factors for RSA, and may contribute to 
a greater understanding of this event.
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RESUMO
Associação entre anticorpo anticardiolipina e mutação C677T na metileno tetrahidrofolato redutase em 
mulheres com aborto espontâneo recorrente: um novo caminho na trombofilia?
CONTEXTO: O aborto espontâneo recorrente já foi associado a vários fatores etiológicos e à trombose 
materna. Fatores de trombofilia adquiridos e hereditários podem ser causas destes eventos.
OBJETIVO: Avaliar a associação entre fatores de trombofilia e aborto espontâneo recorrente. 
TIPO DE ESTUDO: Caso-controle.
LOCAL: Centro de Atenção Integral à Saúde da Mulher, Universidade Estadual de Campinas, São Paulo, 
Brasil.
MÉTODOS: Foram retirados 40 ml de sangue de 88 mulheres com aborto espontâneo recorrente do Ambu-
latório de Aborto Recorrente e 88 mulheres férteis do Ambulatório de Planejamento Familiar, pareadas por 
idade e raça, para pesquisar fatores de trombofilia adquiridos e hereditários. O anticorpo anticardiolipina 
(ACA), anticoagulante lúpico (LA) e a deficiência das proteínas C, S e antitrombina III foram pesquisados 
por ELISA (enzyme-linkek immunosorbent assay), dRVVT (dilute Russel Viper Venom Time, dRVVT) e métodos 
coagulométrico e cromogênico. O ácido desoxirribonucléico (DNA) foi amplificado pela técnica de reação 
em cadeia da polimerase (PCR) para o estudo das mutações fator V de Leiden, G20210A no gene da 
protrombina e C677T no gene da enzima metilenotetrahidrofolato redutase (MTHFR). 
RESULTADOS: O ACA foi encontrado em 11 mulheres com RSA e em uma mulher fértil [OR 12.4 (IC 95% 
1.5 a 98.5)]. A mutação C677T heterozigota foi encontrada em 59 mulheres com RSA e em 35 mulheres 
férteis [OR 3.1 (IC 95% 1.7 a 5.7)]. A presença concomitante do ACA e da mutação C677T heterozigota foi 
encontrada em oito mulheres com aborto espontâneo recorrente e em nenhuma mulher fértil (p < 0,01). 
DISCUSSÃO: O significado da associação entre a mutação heterozigota C677T no gene da MTHFR e o 
anticorpo anticardiolipina não está claro. Pode-se supor que um fator hereditário que, isolado, não pre-
disporia fortemente um indivíduo à trombose poderia, em associação com um fator adquirido, deflagrar 
o processo e intensificar a expressão da trombose.
CONCLUSÕES: O ACA e a mutação C677T heterozigota no gene da MTHFR apresentaram associação 
estatística com RSA. A concomitância destas duas alterações é um novo achado no estudo de fatores 
trombogênicos em aborto espontâneo recorrente. 
PALAVRAS-CHAVE: Metilenotetrahidrofolato redutase (NADPH2). Trombofilia. Trombose. Síndrome antifos-
folipídica. Anticorpos anticardiolipina.
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